Oklahoma Senate Bill SB1306

Oklahoma 2026 Regular Session

• Introduced: 2/2/26
• Refer: 2/3/26

Caption

Prescription drugs; prohibiting insurer from modifying coverage under certain conditions; providing civil penalty; promulgating rules. Effective date.

Summary

SB1306 would create a new section of Oklahoma insurance law governing prescription drug coverage. It prohibits an insurer from changing an insured’s coverage for a prescription drug when the drug was previously preauthorized or was on the insurer’s formulary at the time it was prescribed, the patient has already received the drug, and a practitioner continues to prescribe it. The bill defines key terms such as insurer, practitioner, and prescription drug by reference to existing Oklahoma statutes. Under the bill, prohibited modifications include raising cost-sharing amounts, denying continued coverage, moving the drug to a more restrictive tier, or switching a brand-name drug to a generic after the insured has already qualified for the brand-name drug. The bill allows exceptions if the FDA has raised clinical safety concerns or if the manufacturer has notified the FDA of a discontinuance or potential discontinuance of the drug. Violations would be subject to a civil penalty set by the Insurance Commissioner, who would also be required to adopt rules to implement the law. The act would take effect November 1, 2026.

Impact

SB1306 would add a new consumer-protection requirement to Title 36 of the Oklahoma Statutes, limiting insurers’ ability to alter prescription drug coverage midstream for patients who have already been approved for and are using a medication. It would affect health insurers, insured patients, and prescribing practitioners by preserving coverage terms for certain ongoing therapies, while preserving insurer authority in cases involving FDA safety concerns or drug discontinuation. The bill also expands the Insurance Commissioner’s regulatory role by authorizing civil penalties and requiring rulemaking.

Sentiment

The available context suggests the bill was introduced as a patient-protection measure with no recorded committee debate or votes in the provided materials. Its caption and text indicate a policy goal of stabilizing prescription drug coverage for insured patients, which generally suggests support for continuity of care and predictability in medication access. Because no transcripts or vote history are included, there is no documented opposition or support to characterize beyond the bill’s protective framing.

Contention

The main policy tension in SB1306 is between protecting patients from unexpected coverage changes and preserving insurer flexibility to manage formularies, premiums, and utilization. Supporters would likely favor the bill’s continuity-of-care protections for patients already taking a covered drug, while insurers may object to limits on their ability to change tiers, cost-sharing, or substitute generics. The bill addresses some concerns by allowing changes when the FDA questions safety or when a manufacturer discontinues the drug, but the scope of the prohibition on mid-year coverage changes could still be a point of contention.